Hologic, Inc. (HOLX)
| Market Cap | 19.68B |
| Revenue (ttm) | 5.66B |
| Net Income (ttm) | 2.04B |
| Shares Out | 256.23M |
| EPS (ttm) | 7.81 |
| PE Ratio | 9.95 |
| Forward PE | 17.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,877,354 |
| Open | 76.99 |
| Previous Close | 77.15 |
| Day's Range | 76.61 - 77.96 |
| 52-Week Range | 60.10 - 85.00 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 85.50 (+10.1%) |
| Est. Earnings Date | Nov 3, 2021 |
About HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fus...
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for Hologic stock is "Buy." The 12-month stock price forecast is 85.50, which is an increase of 10.14% from the latest price.
News
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
Hologic (HOLX) closed the most recent trading day at $77.62, moving -0.55% from the previous trading session.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
Hologic (HOLX) closed the most recent trading day at $79.95, moving -0.98% from the previous trading session.
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Hologic (HOLX) Up 5.7% Since Last Earnings Report: Can It Continue?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Hologic (HOLX) Acessa Procedure Gets Anthem Insurance Coverage
Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.
A Quality Exec Comp Plan Lowers The Risk Of Investing In Hologic
Overall, nine out of the 15 Exec Comp Aligned with ROIC Stocks outperformed the S&P 500 from July 15, 2021 through August 11, 2021.
Anthem, Nation's Second Largest Health Plan, Now Covers Hologic's Acessa Procedure as a Treatment for Uterine Fibroids
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that Anthem Blue Cross Blue Shield, the second largest health plan in the United Sta...
Covid testing remains 30 percent of Hologic business: CEO
Hologic CEO Steve MacMillan joins Closing Bell to discuss the company's recent earnings and how persistent Covid testing might continue to be as a major part of Hologic's business. MacMillan also explai...
Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull
Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.
Hologic (HOLX) Q3 Earnings and Revenues Top Estimates
Hologic (HOLX) delivered earnings and revenue surprises of 19.82% and 12.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Hologic Q3 Earnings
Shares of Hologic (NASDAQ:HOLX) increased after the company reported Q3 results. Quarterly Results Earnings per share were up 77.33% year over year to $1.33, which beat the estimate of $1.12.
Hologic Announces Financial Results for Third Quarter of Fiscal 2021
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2021
A Trio of High Return Non-Cyclical Stock Picks
Investors may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are doubling the 20-year high quality...
Breast Health Sales to Aid Hologic's (HOLX) Q3 Earnings
The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.
New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recom...
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #CDC--New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs)
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) Gains As Market Dips: What You Should Know
Hologic (HOLX) closed at $70.37 in the latest trading session, marking a +1.19% move from the prior day.
Will Hologic Stock Grow Further After A 7% Rise In A Month?
The stock price of Hologic, a medical devices company focused on women's health, has seen a 7% rise over the last twenty-one trading days, while it is up just 12% over the last year. Hologic has benefit...
Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark
Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.
European OK's Use Of Saliva Samples With Hologic's Aptima COVID-19 Test
Hologic Inc (NASDAQ: HOLX) has obtained a CE Mark to use saliva samples with its Aptima SARS-CoV-2 assay in Europe. The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the pathogen'...
Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test